CANY
TRAW icon

Caxton Associates (New York)’s Traws Pharma TRAW Stock Holding History

Caxton Associates (New York)’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-152
Closed -$57K – 640
2021
Q1 		$57K Buy
+152
New +$57.3K 0.01% 410

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Caxton Associates (New York)'s TRAW Position: Q2 2021 in Review

Caxton Associates (New York) sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 152 shares — an estimated $57K sold.

Caxton Associates (New York) first reported a position in TRAW in Q1 2021 and held it in 1 quarter. The position peaked at $57K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

  • Caxton Associates (New York) reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
  • Caxton Associates (New York) sold 152 Traws Pharma shares in Q2 2021, an estimated $57K.
  • Caxton Associates (New York) first reported a position in Traws Pharma in Q1 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Traws Pharma position peaked at $57K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on Caxton Associates (New York)'s 13F filing for Q2 2021, filed 16 Aug 2021.